THYMIC CARCINOMA WITH A DEFECTIVE EPSTEIN-BARR-VIRUS ENCODING THE BZLF1 TRANSACTIVATOR

被引:25
作者
PATTON, DF
RIBEIRO, RC
JENKINS, JJ
SIXBEY, JW
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, MEMPHIS, TN USA
[3] ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN USA
[4] ST JUDE CHILDRENS RES HOSP, DEPT VIROL MOLEC BIOL, MEMPHIS, TN USA
[5] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA
[6] UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN USA
关键词
D O I
10.1093/infdis/170.1.7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The diagnosis of Epstein-Barr virus (EBV)-associated carcinomas is often heralded by high antibody titers to the viral replicative antigens, suggesting EBV reactivation may be a factor in tumor evolution. EBV DNA and nuclear antigen was detected in a newly diagnosed thymic carcinoma. Polymerase chain reaction analysis revealed the presence of a rearranged EBV DNA fragment, BamHI WZhet. This rearrangement is found in a defective EBV that up-regulates the BZLF1 (BamHI Z leftward reading frame) gene product in vitro and induces the EBV lytic cycle. Molecular analysis of the EBV termini demonstrated low levels of the lytic (linear) genomic configuration among a predominantly latent (episomal) population at diagnosis. The episomal populations were of uniform molecular weight at diagnosis and relapse, indicating clonal tumor expansion from a single EBV-infected progenitor. The presence within malignant epithelium of defective virus that can disrupt EBV latency, and perhaps cellular gene regulation, suggests a potential mechanism for EBV reactivation and concurrent malignant progression.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 40 条
[1]  
BARRETT ADT, 1986, CURR TOP MICROBIOL, V128, P55
[2]  
BURKE AP, 1990, MODERN PATHOL, V3, P377
[3]   LYMPHOEPITHELIOMA-LIKE CARCINOMA OF THE LUNG [J].
BUTLER, AE ;
COLBY, TV ;
WEISS, L ;
LOMBARD, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1989, 13 (08) :632-639
[4]   STRUCTURE OF DEFECTIVE-DNA MOLECULES IN EPSTEIN-BARR VIRUS PREPARATIONS FROM P3HR-1 CELLS [J].
CHO, MS ;
BORNKAMM, GW ;
HAUSEN, HZ .
JOURNAL OF VIROLOGY, 1984, 51 (01) :199-207
[5]   EPSTEIN-BARR VIRUS (B95-8) DNA .7. MOLECULAR-CLONING AND DETAILED MAPPING [J].
DAMBAUGH, T ;
BEISEL, C ;
HUMMEL, M ;
KING, W ;
FENNEWALD, S ;
CHEUNG, A ;
HELLER, M ;
RAABTRAUB, N ;
KIEFF, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (05) :2999-3003
[6]  
DIMERY IW, 1988, CANCER, V61, P2475, DOI 10.1002/1097-0142(19880615)61:12<2475::AID-CNCR2820611215>3.0.CO
[7]  
2-5
[8]   EXPRESSION OF EPSTEIN-BARR VIRUS-ENCODED PROTEINS IN NASOPHARYNGEAL CARCINOMA [J].
FAHRAEUS, R ;
FU, HL ;
ERNBERG, I ;
FINKE, J ;
ROWE, M ;
KLEIN, G ;
FALK, K ;
NILSSON, E ;
YADAV, M ;
BUSSON, P ;
TURSZ, T ;
KALLIN, B .
INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (03) :329-338
[9]   EPSTEIN-BARR VIRUS BZLF1 TRANS-ACTIVATOR SPECIFICALLY BINDS TO A CONSENSUS AP-1 SITE AND IS RELATED TO C-FOS [J].
FARRELL, PJ ;
ROWE, DT ;
ROONEY, CM ;
KOUZARIDES, T .
EMBO JOURNAL, 1989, 8 (01) :127-132
[10]   A TECHNIQUE FOR RADIOLABELING DNA RESTRICTION ENDONUCLEASE FRAGMENTS TO HIGH SPECIFIC ACTIVITY [J].
FEINBERG, AP ;
VOGELSTEIN, B .
ANALYTICAL BIOCHEMISTRY, 1983, 132 (01) :6-13